Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®)
Top Cited Papers
- 1 March 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in PAIN®
- Vol. 91 (1) , 123-130
- https://doi.org/10.1016/s0304-3959(00)00427-9
Abstract
Oral transmucosal fentanyl citrate (OTFC®; Actiq®) is a drug delivery formulation used for management of breakthrough cancer pain. Previous studies with open-label comparisons indicated OTFC was more effective than patients’ usual opioid for breakthrough pain. The objective of this study wasKeywords
This publication has 11 references indexed in Scilit:
- Defining the clinically important difference in pain outcome measuresPAIN®, 2000
- The Relative Potency of Oral Transmucosal Fentanyl Citrate Compared with Intravenous Morphine in the Treatment of Moderate to Severe Postoperative PainAnesthesia & Analgesia, 1999
- Breakthrough pain: characteristics and impact in patients with cancer painPain, 1999
- Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration studyPain, 1999
- Peak Plasma Concentrations After Oral Morphine: A Systematic ReviewJournal of Pain and Symptom Management, 1998
- Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.Journal of Clinical Oncology, 1998
- Systemic Opioid Therapy for Chronic Cancer PainCNS Drugs, 1998
- Predictive factors in advanced cancer pain treated only by analgesicsPain, 1992
- Absorption and Bioavailability of Oral Transmucosal Fentanyl CitrateAnesthesiology, 1991
- Pharmacokinetics, Pharmacodynamics, and Rational Opioid SelectionAnesthesiology, 1991